Bioequivalence of a Single Subcutaneous Dose of BEPO and REPO in Healthy Male Subjects

NCT02426151 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: BEPO-A
DRUG: REPO-A

Sponsor

LG Life Sciences